Another FDA mini-pause for Bayer’s menopause candidate?

28th July 2025 Uncategorised 0

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet drug approval deadlines. The latest example is its failure to rule on Bayer’s menopause treatment, elinzanetant.

More: Another FDA mini-pause for Bayer’s menopause candidate?
Source: fierce